ANDA 211624, held by Quagen. Fosaprepitant Dimeglumine.
As of Nov 15, 2026, ANDA 211624 (Fosaprepitant Dimeglumine), held by Quagen, was first approved by FDA on Sep 5, 2019, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 5, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fosaprepitant DimeglumineEQ 150MG BASE/VIAL · powder;intravenous | Fosaprepitant Dimeglumine | Discontinued |
| Jan 6, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 5, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
